A. De Matteis

3.9k total citations · 1 hit paper
58 papers, 2.1k citations indexed

About

A. De Matteis is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, A. De Matteis has authored 58 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 32 papers in Cancer Research and 17 papers in Genetics. Recurrent topics in A. De Matteis's work include Cancer Treatment and Pharmacology (31 papers), Breast Cancer Treatment Studies (30 papers) and Estrogen and related hormone effects (15 papers). A. De Matteis is often cited by papers focused on Cancer Treatment and Pharmacology (31 papers), Breast Cancer Treatment Studies (30 papers) and Estrogen and related hormone effects (15 papers). A. De Matteis collaborates with scholars based in Italy, United States and Malaysia. A. De Matteis's co-authors include Francesco Perrone, Massimo Di Maïo, Giorgio Mustacchi, Francesco Nuzzo, Ermelinda De Maio, Ciro Gallo, Sabino De Placido, Maria Carmela Piccirillo, Alfonso M. Pluchinotta and Antonio Giordano and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

A. De Matteis

57 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials

2015 330 citations Massimo Di Maïo, Ciro Gallo et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. De Matteis Italy	21	1.2k	809	533	356	317	58	2.1k
Christine D. Berg United States	18	1.2k 1.0×	768 0.9×	727 1.4×	390 1.1×	422 1.3×	43	2.5k
Javaid Iqbal Canada	15	1.1k 0.9×	782 1.0×	430 0.8×	206 0.6×	286 0.9×	23	1.8k
J. Cuzick United Kingdom	15	1.2k 1.0×	812 1.0×	695 1.3×	314 0.9×	192 0.6×	40	2.1k
Reena S. Cecchini United States	20	1.8k 1.5×	959 1.2×	1.1k 2.0×	422 1.2×	393 1.2×	49	2.9k
Caroline Lohrisch Canada	23	1.3k 1.1×	934 1.2×	410 0.8×	408 1.1×	296 0.9×	80	2.1k
Indraneel Mittra India	26	1.3k 1.1×	872 1.1×	296 0.6×	338 0.9×	457 1.4×	84	2.6k
C.-M. Rudenstam Sweden	18	1.2k 1.0×	746 0.9×	437 0.8×	304 0.9×	242 0.8×	28	1.7k
Neelima Denduluri United States	23	1.7k 1.4×	821 1.0×	203 0.4×	700 2.0×	379 1.2×	67	2.8k
John F. Sandbach United States	15	1.5k 1.2×	864 1.1×	413 0.8×	360 1.0×	661 2.1×	32	2.4k
José Bines Brazil	22	2.7k 2.2×	1.4k 1.7×	694 1.3×	1.0k 2.8×	549 1.7×	94	3.7k

Countries citing papers authored by A. De Matteis

Since Specialization

Citations

This map shows the geographic impact of A. De Matteis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. De Matteis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. De Matteis more than expected).

Fields of papers citing papers by A. De Matteis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. De Matteis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. De Matteis. The network helps show where A. De Matteis may publish in the future.

Co-authorship network of co-authors of A. De Matteis

This figure shows the co-authorship network connecting the top 25 collaborators of A. De Matteis. A scholar is included among the top collaborators of A. De Matteis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. De Matteis. A. De Matteis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Perrone, Francesco, Claudio Jommi, Massimo Di Maïo, et al.. (2016). The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy. Annals of Oncology. 27(12). 2224–2229. 108 indexed citations

Maïo, Massimo Di, Ciro Gallo, Natasha B. Leighl, et al.. (2015). Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials. Journal of Clinical Oncology. 33(8). 910–915. 330 indexed citations breakdown →

Perrone, Francesco, Francesco Nuzzo, Francesca Di Rella, et al.. (2014). Weekly Docetaxel (Wd) Vs Cmf As Adjuvant Chemotherapy for Elderly Early Breast Cancer (Ebc) Patients (Pts): Final Results from the Randomised Phase 3 Elda Trial. Annals of Oncology. 25. iv86–iv86. 1 indexed citations

Clavarezza, Matteo, Giorgio Mustacchi, Andrea Casadei‐Gardini, et al.. (2012). Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study. BMC Cancer. 12(1). 216–216. 6 indexed citations

Nuzzo, Francesco, Alessandro Morabito, Ermelinda De Maio, et al.. (2007). Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: Safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology. 66(2). 171–180. 20 indexed citations

Cazzaniga, Marina Elena, Giorgio Mustacchi, P. Pronzato, et al.. (2007). Adjuvant treatment of early breast cancer: do the St Gallen recommendations influence clinical practice? Results from the NORA study. Annals of Oncology. 18(12). 1976–1980. 7 indexed citations

Morabito, Alessandro, Maria Carmela Piccirillo, Carmen Pacilio, et al.. (2007). First-Line Chemotherapy for HER-2–Negative Metastatic Breast Cancer Patients Who Received Anthracyclines as Adjuvant Treatment. The Oncologist. 12(11). 1288–1298. 5 indexed citations

Cazzaniga, Marina Elena, Giorgio Mustacchi, P. Pronzato, et al.. (2006). Adjuvant systemic treatment of early breast cancer: the NORA study. Annals of Oncology. 17(9). 1386–1392. 15 indexed citations

Pignata, Sandro, Sabino De Placido, R. Biamonte, et al.. (2006). Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC Cancer. 6(1). 5–5. 99 indexed citations

10.

Pacilio, Carmen, Alessandro Morabito, Francesco Nuzzo, et al.. (2006). Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial. British Journal of Cancer. 94(9). 1233–1236. 21 indexed citations

11.

Bianco, Antonio, A. De Matteis, Luigi Manzione, et al.. (2006). Sequential epirubicin-docetaxel-CMF as adjuvant therapy of early breast cancer: Results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology. 24(18_suppl). LBA520–LBA520. 20 indexed citations

12.

Tampellini, Marco, Alfredo Berruti, Raffaella Bitossi, et al.. (2006). Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients. Breast Cancer Research and Treatment. 98(3). 241–248. 29 indexed citations

13.

Normanno, Nicola, Massimo Di Maïo, Ermelinda De Maio, et al.. (2005). Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocrine Related Cancer. 12(4). 721–747. 226 indexed citations

14.

Cazzaniga, Marina Elena, P. Pronzato, A. De Matteis, et al.. (2004). Patterns of Relapse and Modalities of Treatment of Breast Cancer: The ‘IRIS’ Project, a Multicenter Observational Study. Oncology. 66(4). 260–268. 6 indexed citations

15.

Mustacchi, Giorgio, Rita Ceccherini, Stefano Milani, et al.. (2003). Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Annals of Oncology. 14(3). 414–420. 146 indexed citations

16.

Florio, Salvatore, Roberto Ciarcia, Giovanni Vacca, et al.. (2003). MPA increases idarubicin‐induced apoptosis in chronic lymphatic leukaemia cells via caspase‐3. Journal of Cellular Biochemistry. 89(4). 747–754. 4 indexed citations

17.

Matteis, A. De, Francesco Nuzzo, Giuseppe D’Aiuto, et al.. (2002). Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast. Cancer. 94(4). 895–901. 10 indexed citations

18.

Tampellini, Marco, Alfredo Berruti, G. Gorzegno, et al.. (2001). Independent Factors Predict Supranormal CA 15-3 Serum Levels in Advanced Breast Cancer Patients at First Disease Relapse. Tumor Biology. 22(6). 367–373. 14 indexed citations

19.

Matteis, A. De, Marco Montella, V. Labonia, et al.. (1998). Multimodal Treatment Strategy for Locally Advanced Breast Cancer. Journal of Chemotherapy. 10(6). 476–483. 2 indexed citations

20.

Boccardo, Francesco, A. Rubagotti, Allison Perrotta, et al.. (1994). Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: Results of a multicentric Italian study. Annals of Oncology. 5(4). 337–342. 92 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact